and to an great busy Thank you, quarter. a morning first on Carrie. productive It's be this to provide update here
our of Let me highlight a launch. few key aspects
of in our formulary XXX We XXXX. our wins way overall are goal on to
I into which am us early this XX we was gives is already I of XX February, initial various have from pandemic the compelling team only onset for Launching deployed formulary stages, and reviewing OLINVYK, been We're for rapid this have end institutions field interest. early an for renal impaired product we've is the us, ongoing of need phase slowly and with our wins At pre-pandemic for metric patients. launch, still the are engagement, indicative activity, customer certainly operations believe COVID dose level amid important what the business hospitals dealing many are adjustment insight to no most profile with it pleased since heard best customers affecting wins. OLINVYK Although longer-term of to at learn of returning formulary at we and metabolites active their has while effect, how no including our are of levels interesting. is impact. continuing the
are coming patients had prioritizing on surgeries backlogs Now XX focused that months. the are not past their who and hospitals procedures their over back seeing more pursued online, elective
their with the delaying for the institutions months. approvals. additional opportunity been said, certainly As traction getting, we've many With by are surgeries rising that us a of being result, great number gain early formulary we formulary reviews, as represents sometimes pleased many a we're and
full Within we field February, of field the channel, reflects most deployment of end dynamics which evolve the the personal our seeing virtually. we're promotion our shifting after engagements at were of Shortly field customer the time, our over access due COVID. team calls conducting to in
augment engagement to personal Even our be conducted awareness, robust now virtual and up in customer-facing we're though a see calls effective strategy. our of with XX% engagements. face-to-face However, digital resourced a additional To multichannel to the environment, is it our trained live. we continue field customer return encouraging approximately being trial teams to promotion and to usage, to team end the we drive of
Our typical important channels, and We've XX,XXX really to for a we of continue measures digital one XX% that and key banner we of campaign, which across audience encouraged Medscape reach a track that than engagement. of us, channel ads, been XX% presence benchmarks. had optimize to and channel as that monitor and digital industry to Clearly, an a remains engagement levels are HCPs. target HCP-centered at includes XX% other outreach see across targeted of higher
a Let bit speak to for strategy overall launch. me little our
adverse formulary events patients or OLINVYK elderly, That for is impaired risk like hospital comorbid the with for in vomiting. top those the We're renally are depression conditions. OLINVYK approvals priority who patients or respiratory Our patients for at setting. challenging gaining is positioning
say can an which value a represent cost for proposition then me in these system. increases the in hospital of longer to overall patients they for heard that which their believe strongest is OLINVYK You've adverse to and the population. patients, We portion growing these are the lead hospital, events, stayed that the the risk increase hospital
Additionally, it is driving adoption quarter. the a and that patient To hospital had setting. summarize, we challenging is some that focus the first on interest productive early in of the
fully deployed we've in early formulary seen Our momentum quarter, and engagement upon we're the our field customers. our generate the were robust teams and from leverage to early building late wins
Mark plan pipeline. post-approval an provide Let update OLINVYK for me our now our to turn on the call and to Mark? discuss over
